Details for Patent: 8,633,194

Which drugs does patent 8,633,194 protect, and when does it expire?

Patent 8,633,194 protects XYZAL ALLERGY 24HR and is included in one NDA.

This patent has thirty patent family members in twenty-four countries.

Summary for Patent: 8,633,194

Patent landscape, scope, and claims:

Title:	Pharmaceutical composition of piperazine derivatives
Abstract:	The present invention relates to a liquid composition containing an active substance belonging to the family of substituted benzhydryl piperazines with reduced amounts of preservatives.
Inventor(s):	Fanara; Domenico (Wanze, BE), Scouvart; Jean (Brussels, BE), Poulain; Claire (Brussels, BE), Deleers; Michel (Linkebeek, BE)
Assignee:	UCB Pharma, S.A. (Brussels, BE)
Application Number:	10/599,451
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,633,194
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 8,633,194

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Chattem Sanofi	XYZAL ALLERGY 24HR	levocetirizine dihydrochloride	SOLUTION;ORAL	209090-001	Jan 31, 2017		OTC	Yes	Yes	8,633,194		Y

Foreign Priority and PCT Information for Patent: 8,633,194

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	04016519	Jul 14, 2004

PCT Information
PCT Filed	July 06, 2005	PCT Application Number:	PCT/EP2005/007340
PCT Publication Date:	January 19, 2006	PCT Publication Number:	WO2006/005507

International Family Members for US Patent 8,633,194

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	049846
Austria	E443512
Australia	2005261953
Brazil	PI0513257